K
Kriya Therapeutics
Innovative gene therapies targeting prevalent chronic diseases
News
Open roles
Kriya Therapeutics in the Morrisville ecosystem
The Kriya Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
- AAAsia Alpha
Foresite Capital- AMAmplo
- DPDexcel Pharma
- PMPaul Manning
- NCNarya Capital
- QLQVT Financial LP
- BVBluebird Ventures
Series B and later10 investors entered at this stage
- WPWoodline Partners
- LCLightswitch Capital
Premji Invest- CCCAM Capital
- PCPatient Square Capital
- JFJDRF T1D Fund
- TCThiel Capital
- TCTranshuman Capital
Alumni Ventures- HOHongkou
Source: Dealroom Talent Intelligence.
Patents
11 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Kriya Therapeutics was the backer or acquirer, 2022–2023. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
3 deals across Kriya Therapeutics's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where Kriya Therapeutics deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
Kriya Therapeutics's portfolio, mapped.
See Kriya Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


